Tarsus Pharmaceuticals, Inc.
TARS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001819790
In the last 90 days, Tarsus Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 256 institutions reported holding it in 13F filings for Q2 2026, worth $2.98B in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Tarsus Pharmaceuticals, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 69 | 74 | +5 |
| Shares | 20.5M | 20.1M | −473.3K (−2.3%) |
| Value | $301.0M | $252.1M | −$48.9M (−16.2%) |
New holders (10)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Oconnor LLC | 98,175 | $1.23M | 0.03% |
| D. E. Shaw & Co., Inc. | 17,567 | $220.8K | 0.00% |
| Squarepoint Ops LLC | 13,937 | $175.2K | 0.00% |
| Millennium Management LLC | 13,387 | $168.0K | 0.00% |
| HSBC Holdings PLC | 11,622 | $148.5K | 0.00% |
| Qube Research & Technologies Ltd | 10,352 | $130.1K | 0.00% |
| Huntington National Bank | 1,501 | $18.9K | 0.00% |
| Aquatic Capital Management LLC | 400 | $5.00K | 0.00% |
| Spire Wealth Management | 103 | $1.29K | 0.00% |
| Russell Investments Group, Ltd. | 25 | $314 | 0.00% |
Sold out (5)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Two Sigma Advisers, LP | 26,700 | $391.4K |
| Janney Montgomery Scott LLC | 11,640 | $171.0K |
| US Bancorp | 79 | $1.16K |
| IFP Advisors, Inc | 30 | $1.00K |
| Signaturefd, LLC | 13 | $191 |